Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis

@article{Renehan2004InsulinlikeGF,
  title={Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis},
  author={Andrew G. Renehan and Marcel Zwahlen and Christoph E. Minder and Sarah T O'dwyer and Stephen M. Shalet and Matthias Egger},
  journal={The Lancet},
  year={2004},
  volume={363},
  pages={1346-1353}
}
View on Elsevier
doi.org
1,574 Citations
Highly Influential Citations
51
Background Citations
555
Methods Citations
24
Results Citations
75

1,574 Citations

Citation Type

Citation Type

Insulin-like Growth Factor ( IGF )-I , IGF-II , IGF Binding Protein-3 , and Risk of Colorectal Cancer : a Nested Case-control Study in the JACC Study
TLDR
There is no association of IGF-I, IGF-II, and IGFBP-3 with colorectal cancer risk in the Japanese population according to the JACC Study in Japan, and evidence supporting this hypothesis is not obtained.
Insulin-like growth factor (IGF)-I, IGF binding protein-3, and breast cancer risk: eight years on.
TLDR
A cumulative meta-analysis demonstrates that earlier reported positive associations between IGFBP-3 and pre-menopausal breast cancer risk now seem less clear as large-size cohorts are published, and the reasons are complex and include differences in study design, lack of standardisation between assays, and variations in IGF BP-3 proteolytic activity.
Serum Insulin-like Growth Factor (IGF)-I and IGF-Binding Protein-3 Concentrations and Prostate Cancer Risk: Results from the European Prospective Investigation into Cancer and Nutrition
TLDR
In this large nested case-control study, serum IGF-I concentration is not strongly associated with prostate cancer risk, although the results are compatible with a small increase in risk, particularly for advanced-stage disease.
Phenotypes and genotypes of insulin-like growth factor 1, IGF-binding protein-3 and cancer risk: evidence from 96 studies
TLDR
Circulating levels of IGF1, IGF BP3 and IGFBP3 A−202C play a crucial role in carcinogenesis and could serve as susceptibility biomarkers for cancer development.
Insulin-like Growth Factor-1, IGF-binding Protein-3, C-peptide and Colorectal Cancer: a Case-control Study.
TLDR
Evidence is provided for an association of insulin-related biomarkers with colorectal cancer risk and they point to consideration as candidate predictor markers.
Plasma Insulin-Like Growth Factor-1 (IGF-1), IGF-Binding Protein-3, and the Risk of Prostate Cancer: A Matched Case-Control Study in a Korean Population
TLDR
Plasma IGFBP-3 levels were inversely associated with the risk of prostate cancer and the likelihood for high-risk disease, suggesting that IGF BP-3 plays a protective role against prostate cancer in the Korean population.
Prostate Cancer Risk in Relation to Insulin-like Growth Factor (IGF)-I and IGF-Binding Protein-3: A Nested Case-Control Study in Large Scale Cohort Study in Japan (JACC Study)
TLDR
Investigation of the influence of serum IGF-I and IGFBP-3 on prostate cancer risk in a casecontrol study nested within a large-scale cohort in Japan found that serum levels were not thought to be associated with risk of prostate cancer.
Association of circulating insulin-like growth factor 1 and insulin-like growth factor binding protein 3 with the risk of ovarian cancer: A systematic review and meta-analysis.
TLDR
As no significant association of IGF-1/IGFBP-3 with ovarian cancer risk was identified in the present meta-analysis of existing studies, more studies with greater quality are required in the future.
Serum Concentrations of Insulin-Like Growth Factor and Insulin-Like Growth Factor Binding Protein 3 and Recurrent Colorectal Adenomas
TLDR
Results showed an unexpected null association, or even the suggestion of a reduction in risk for recurrent adenoma, with not just high IGFBP-3 concentration but also with high levels of IGF-I.
Circulating Insulin-like Growth Factor (IGF)-I and IGF Binding Protein (IGFBP)-3 Levels and Postmenopausal Breast Cancer Risk in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial (PLCO) Cohort
TLDR
IGF-I and the IGF-I/IGFBP-3 molar ratio were positively, although not statistically significantly, associated with postmenopausal breast cancer risk.
...
...

References

SHOWING 1-10 OF 58 REFERENCES
Plasma insulin-like growth factor 1, insulin-like growth factor binding protein 3, and risk of colorectal cancer: a prospective study in northern Sweden
TLDR
The results support earlier findings of increased risk of colon cancer in subjects with elevated plasma IGF-1, and do not support the hypothesis that the risk of rectal cancer could also be directly related to IGF- 1 levels.
Plasma insulin-like growth factor-I, insulin-like growth factor-binding proteins, and prostate cancer risk: a prospective study.
TLDR
Prostate cancer risk is increased in men with elevated plasma IGF-I, and this association was particularly strong in younger men in this study, suggesting that circulating IGF-i may be specifically involved in the early pathogenesis of prostate cancer.
Re: Insulin-like growth factor-I (IGF-I) and IGF binding protein-3 as predictors of advanced-stage prostate cancer
TLDR
Circulating levels of IGF-I and IGFBP-3 may predict the risk of developing advanced-stage prostate cancer, but their utility for screening patients with incident prostate cancer may be limited.
Serum levels of insulin-like growth factor I (IGF-I), IGF-II, IGF-binding protein-3, and prostate-specific antigen as predictors of clinical prostate cancer.
TLDR
The data suggest that IGF-II may inhibit both prostate growth and development of prostate cancer, which is inconsistent with increased ascertainment in men with large prostates as the source of greater prostate cancer risk associated with IGF-I.
Insulin-like growth factor I (IGF-I), IGF-binding proteins, and breast cancer.
TLDR
In premenopausal women, elevated serum IGF-I and IGFBP-3 are associated with increased breast cancer risk, whereas elevated serum IGBP-2 is inversely associated with risk of postmenopausal breast cancer.
Serum insulin-like growth factor (IGF) and IGF-binding protein levels and risk of lung cancer: a case-control study nested in the beta-Carotene and Retinol Efficacy Trial Cohort.
TLDR
A trend toward a positive association with IGFBP-3 level is unexpected and requires further investigation, and the possibility that risk of lung cancer in nonsmokers may be related to IGF-I levels is not excluded.
Prospective study of IGF-I, IGF-binding proteins, and breast cancer risk, in Northern and Southern Sweden
TLDR
The results do not support the hypothesis that elevated plasma insulin levels, and reduced levels of IGF BP-1 and IGFBP-2, are associated with increased breast cancer risk, but suggest a possible association with postmenopausal breast cancers risk, possibly among ERT/HRT users only.
Circulating concentrations of insulin-like growth factor I and risk of breast cancer
Serum C-peptide, insulin-like growth factor (IGF)-I, IGF-binding proteins, and colorectal cancer risk in women.
TLDR
Ch Chronically high levels of circulating insulin and IGFs associated with a Western lifestyle may increase colorectal cancer risk, possibly by decreasing IGFBP-1 and increasing the bioactivity of IGF-I.
Response: More About: Prospective Study of Colorectal Cancer Risk in Men and Plasma Levels of Insulin-Like Growth Factor (IGF)-I and IGF- Binding Protein-3
TLDR
Ass associations of plasma levels of IGF-I and IGFBP-3 with the risk of colorectal cancer are suggested to be consistent during the first and the second 7-year follow-up intervals and among younger and older men.
...
...